Previous 10 | Next 10 |
AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD TM ) AC Immune ...
2023-03-18 09:00:00 ET Summary ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far. That could change, and the stock could rise, but it is just too ris...
2023-03-16 07:57:43 ET AC Immune press release ( NASDAQ: ACIU ): FY Non-GAAP EPS of -CHF 0.81. Revenue of CHF 3.9M. For further details see: AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-be...
2023-03-15 11:30:26 ET Major earning expected before the bell on Thursday include: Cresco Labs ( OTCQX:CRLBF ) Dollar General ( DG ) Jabil ( JBL ) Hello Group ( MOMO ) Williams-Sonoma ( WSM ) For further details see: Notable earnings befor...
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8 , 202 3 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for n...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer program Target ALS Foundation grant supports collaboration...
AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, Februar y 2 , 202 3 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, to...
AC Immune ( NASDAQ: ACIU ) said its ACI-24.060 anti-amyloid beta (Abeta) vaccine for Alzheimer's disease (AD) showed positive initial interim safety and immunogenicity in a phase 1b/2 trial called ABATE. ABATE will now be expanded to include patients with Down syndrome ...
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort ACI-24.060 was general...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...